SEATTLE, WASHINGTON—When French scientists presented the results from an Ebola drug trial at a press conference on Monday, they did so with plenty of caveats, but their message was hopeful: The drug, favipiravir, appeared to lower mortality in people with low and medium-high levels of virus in their blood, the researchers told journalists at the Conference on Retroviruses and Opportunistic Infections (CROI) here.
But when study leader Denis Malvy of the University of Bordeaux in France presented more details of the results at CROI, many colleagues were underwhelmed. Several scientists criticized the evidence as well as the design of the trial, which is ongoing at four clinics in Guinea. “It doesn’t tell us anything,” said epidemiologist Scott Hammer of Columbia University, who chairs the meeting.
In his presentation, Malvy focused on a group of 40 patients who began the trial with lower viral loads than 29 others who clearly did not benefit from favipiravir. As he explained on Monday, only six of those 40 patients died—half of what was expected based on similar patients treated at the same clinics over the past 3 months. What’s more, after 4 days of starting treatment on favipiravir, an influenza drug, 51% of these patients had such low levels of the virus in their blood that the standard test could no longer detect it. “There was a signal that monotherapy with favipiravir may decrease viral load,” Malvy said.